Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

• Status: Completed
• Trial end date: 2006-04-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Viralytics

Criteria

Inclusion Criteria:

• stage IV melanoma (AJCC classification)

• minimum of 2 sc metastases

• failure or refusal of standard chemotherapy

• ECOG score of 0 or 1

• other

Exclusion Criteria:

• metastatic CNS disease

• ocular or mucosal melanoma

• immunodeficiency

• splenectomy

• other